The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
 
Henry C. Pitot
No Relationships to Disclose
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; Regeneron; Sanofi; TRACON Pharma
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); TRACON Pharma (Inst)
 
Claudio Zanna
Employment - Debiopharm Group
 
Jeffrey Mark Brill
Employment - Ascenta Therapeutics
 
Gregoire Vuagniaux
Employment - Debiopharm Group
 
Elisabeth Rouits
Employment - Debiopharm Group
 
J. Mel Sorensen
Employment - Ascenta Therapeutics
 
David C. Smith
Research Funding - Abraxis BioScience (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Oncogenex (Inst); OncoMed (Inst); PSMA Development Company (Inst); Tekmira (Inst); Teva (Inst)